Curcumin improves sclerosing cholangitis in Mdr2 −/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Background and aim: Chronic cholangiopathies have limited therapeutic options and represent an important indication for liver transplantation. Curcumin, the yellow pigment of the spice turmeric, has pleiotropic actions and attenuates hepatic damage in animal models of chemically-induced liver injury. Whether curcumin has beneficial effects in cholangiopathies is unknown. Methods: Potential anticholestatic, anti-inflammatory and antifibrotic mechanisms of curcumin were explored in vivo in Mdr2 −/− mice as a murine model of chronic cholangiopathy; as well as in vitro in a cholangiocyte cell line (HuCCT1) and portal myofibroblasts (MFBs) isolated from Mdr2 −/− mice. Results: Liver damage, cholestasis and fibrosis were reduced in Mdr2 −/− mice after curcumin feeding. Moreover, curcumin inhibited cholangiocyte proliferation and expression of activation marker vascular cell adhesion molecule-1 in Mdr2 −/− mice. Curcumin—similar to PPARγ synthetic agonist troglitazone—directly inhibited TNF-α-induced inflammatory activation of cholangiocytes in vitro, whereas these beneficial effects of curcumin were largely blocked by a PPARγ synthetic antagonist. In addition, curcumin blocked proliferation and activation of portal MFBs by inhibiting ERK1/2 phosphorylation, thus contributing to reduced fibrogenesis. Conclusions: These results show that curcumin may have multiple targets in liver including activation of PPARγ in cholangiocytes and inhibition of ERK1/2 signalling in MFBs, thereby modulating several central cellular events in a mouse model of cholangiopathy. Targeting these pathways may be a promising therapeutic approach to cholangiopathies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hao (2015) · doi:10.1002/14651858 · Cited by 11,321
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Multiple biological activities of curcumin: A short review
Maheshwari, R. K., Singh, A. K., Gaddipati, J., & Srimal, R. C. (2006) · Life Sciences · doi:10.1016/j.lfs.2005.12.007 · Cited by 1,674
Bile salt transporters: molecular characterization, function, and regulation
Trauner, M., & Boyer, J. L. (2003) · Physiological Reviews · doi:10.1152/physrev.00027.2002 · Cited by 999
Self-citationPeroxisome proliferator-activated receptors and hepatic stellate cell activation
Miyahara, T., Schrum, L., Rippe, R., Xiong, S., Yee, H. F., Motomura, K., Anania, F. A., Willson, T. M., & Tsukamoto, H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m006577200 · Cited by 473
Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440
Marra, F., Efsen, E., Romanelli, R. G., Caligiuri, A., Pastacaldi, S., Batignani, G., Bonacchi, A., Caporale, R., Laffi, G., Pinzani, M., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.9365 · Cited by 409
Hazra, S., Xiong, S., Wang, J., Rippe, R. A., Krishna, V., Chatterjee, K., & Tsukamoto, H. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310284200 · Cited by 320
Safadi, R., Ohta, M., Alvarez, C. E., Fiel, M. I., Bansal, M., Mehal, W. Z., & Friedman, S. L. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.062 · Cited by 239 · cited 1×
“mice correlated with reduced CD11b and CD4 positivity. In addition, direct interaction of HSCs with CD8 positive lymphocytes was suggested to play an important role in liver fibrosis.”
BackgroundFibrogenesis I. New insights into hepatic stellate cell activation: the simple becomes complex
Eng, F. J., & Friedman, S. L. (2000) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.2000.279.1.g7 · Cited by 222
Cited by
Protective Effects of Indian Spice Curcumin Against Amyloid-β in Alzheimer’s Disease
Reddy, P. H., Manczak, M., Yin, X., Grady, M. C., Mitchell, A., Tonk, S., Kuruva, C. S., Bhatti, J. S., Kandimalla, R., Vijayan, M., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-170512 · Cited by 354
Novel therapeutic targets for cholestatic and fatty liver disease
Trauner, M., & Fuchs, C. D. (2022) · Gut · doi:10.1136/gutjnl-2021-324305 · Cited by 204
Self-citationBaghdasaryan, A., Fuchs, C. D., Österreicher, C. H., Lemberger, U. J., Halilbasic, E., Påhlman, I., Graffner, H., Krones, E., Fickert, P., Wahlström, A., et al. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.024 · Cited by 187
Self-citationNuclear receptors as therapeutic targets in liver disease: are we there yet?
Rudraiah, S., Zhang, X., & Wang, L. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103209 · Cited by 87
“Curcumin, an active ingredient in turmeric, is another PPARγ agonist that inhibits portal myofibroblast proliferation in a mouse model of chronic cholangiopathy (63).”
Fuchs, C. D., Paumgartner, G., Mlitz, V., Kunczer, V., Halilbasic, E., Leditznig, N., Wahlström, A., Ståhlman, M., Thüringer, A., Kashofer, K., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314553 · Cited by 76
Self-citation
Metadata
- Authors
- Baghdasaryan, A., Claudel, T., Kosters, A., Gumhold, J., Silbert, D., Thüringer, A., Leski, K., Fickert, P., Karpen, S. J., & Trauner, M.
- Venue
- Gut
- Publisher
- BMJ
- Published
- 2010-03-23
- Volume
- 59
- Issue
- 4
- Pages
- 521-530
- ISSN
- 0017-5749 (ISSN-L)
- 1468-3288
- OpenAlex
- W2138950515
- Cited by
- 96
- References
- 13
- FWCI
- 5.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Curcumin improves sclerosing cholangitis in Mdr2 −/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. https://app.cochat.ai/papers/10.1136/gut.2009.186528
- The paper
- Baghdasaryan, A., Claudel, T., Kosters, A., Gumhold, J., Silbert, D., Thüringer, A., Leski, K., Fickert, P., Karpen, S. J., & Trauner, M. (2010). Curcumin improves sclerosing cholangitis in Mdr2 −/− mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. Gut. https://doi.org/10.1136/gut.2009.186528
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.